Table 1 Demographic and clinical features of this study subjects.
From: MicroRNA-146a expresses in interleukin-17 producing T cells in rheumatoid arthritis patients
disease duration Larsen grade K/L score | CRP | ESR | synovium | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
subject | age | sex | RF | PBMC | medication | ||||||
(yr) | for RA | for OA | (mg/ml) | (mm/hr) | (source) | ||||||
RA1 | 76 | F | 4 | 0.53 | 45 | 209.3 | â—‹ | MTX, NSAIDs | |||
RA2 | 69 | M | 3 | 0.31 | 52 | 22.9 | â—‹ | bucillamine, NSAIDs | |||
RA3 | 59 | M | 16 | 3.53 | no data | 49.5 | â—‹ | MTX, predonisone, NSAIDs | |||
RA4 | 59 | F | 2 | 4.12 | 74 | 129.2 | â—‹ | salazosulfapyridine | |||
RA5 | 64 | M | 17 | 2.57 | 48 | 65.3 | â—‹ | bucillamine, NSAIDs | |||
RA6 | 77 | F | 3 | 0.16 | 66 | 160.9 | â—‹ | â—‹ (knee) | salazosulfapyridine | ||
RA7 | 63 | F | 14 | 0.33 | 21 | <6.0 | â—‹ (knee) | infliximab | |||
RA8 | 54 | M | 3 | 3.07 | no data | no data | â—‹ (elbow) | MTX, predonisone, NSAIDs | |||
RA9 | 79 | M | 5 | 0.03 | 8 | 6.1 | â—‹ (wrist) | NSAIDs | |||
RA10 | 74 | F | 15 | 0.33 | 27 | no data | â—‹ (knee) | bucillamine, NSAIDs | |||
RA11 | 59 | F | 5 | 3.55 | 61 | 60.8 | â—‹ (knee) | MTX, bucillamine, predonisone, NSAIDs | |||
OA1 | 74 | F | â—‹ | NSAIDs | |||||||
OA2 | 78 | F | â—‹ | â—‹ (knee) | NSAIDs | ||||||
OA3 | 83 | F | â—‹ | â—‹ (knee) | NSAIDs | ||||||
OA4 | 71 | F | â—‹ (knee) | NSAIDs | |||||||
OA5 | 76 | M | â—‹ | NSAIDs | |||||||
OA6 | 70 | F | â—‹ | NSAIDs | |||||||
OA7 | 71 | F | â—‹ | NSAIDs | |||||||
OA8 | 74 | F | â—‹ (knee) | NSAIDs | |||||||
OA9 | 70 | F | â—‹ (knee) | NSAIDs | |||||||
OA10 | 71 | F | â—‹ (knee) | NSAIDs | |||||||